Fig. 3
From: Protein degradation: expanding the toolbox to restrain cancer drug resistance
Protein degradation modulates drug metabolism. Drug metabolism can be categorized into Phase I (oxidation, reduction, and hydrolysis) and Phase II (posttranslational modification), requiring different classes of drug metabolic enzymes. In Phase I drug metabolism, CHIP and AMFR can ubiquitinate the CYP3A family for degradation. In Phase II, SULT1A3 is regulated by ubiquitin-dependent protein degradation